Li ZJ, Wang LQ, Li YZ, Wang CY, Huang JZ, Yu NZ, Long X. Application of adipose-derived stem cells in treating fibrosis. World J Stem Cells 2021; 13(11): 1747-1761 [PMID: 34909121 DOI: 10.4252/wjsc.v13.i11.1747]
Corresponding Author of This Article
Xiao Long, MD, PhD, Doctor, Professor, Surgeon, Department of Plastic and Reconstructive Surgery, Peking Union Medical College Hospital of Peking Union Medical College and Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Dongcheng District, Beijing 100730, China. pumclongxiao@126.com
Research Domain of This Article
Surgery
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Zhu-Jun Li, Li-Quan Wang, Yun-Zhu Li, Chen-Yu Wang, Jiu-Zuo Huang, Nan-Ze Yu, Xiao Long, Department of Plastic and Reconstructive Surgery, Peking Union Medical College Hospital of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China
Author contributions: Long X and Li ZJ designed the report; Li ZJ, Wang LQ, Li YZ, Wang CY, Huang JZ and Yu NZ collected data and wrote the paper; all authors actively reviewed and revised the manuscript and approved the finally submitted manuscript.
Supported bythe National Natural Science Foundation of China, No. 81670444; and the CAMS Innovation Fund for Medical Sciences (CIFMS), No. 2020-I2M-C&T-A-004.
Conflict-of-interest statement: All the authors declare that they have no competing interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao Long, MD, PhD, Doctor, Professor, Surgeon, Department of Plastic and Reconstructive Surgery, Peking Union Medical College Hospital of Peking Union Medical College and Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Dongcheng District, Beijing 100730, China. pumclongxiao@126.com
Received: February 25, 2021 Peer-review started: February 25, 2021 First decision: May 5, 2021 Revised: May 18, 2021 Accepted: November 15, 2021 Article in press: November 15, 2021 Published online: November 26, 2021 Processing time: 272 Days and 19.4 Hours
Abstract
Fibrosis is the hyperactivation of fibroblasts that results in excessive accumulation of extracellular matrix, which is involved in numerous pathological changes and diseases. Adipose-derived stem cells (ASCs) are promising seed cells for regenerative medicine due to their bountiful source, low immunogenicity and lack of ethical issues. Their anti-fibrosis, immunomodulation, angiogenesis and other therapeutic effects have made them suitable for treating fibrosis-related diseases. Here, we review the literature on ASCs treating fibrosis, elaborate and discuss their mechanisms of action, changes in disease environment, ways to enhance therapeutic effects, as well as current preclinical and clinical studies, in order to provide a general picture of ASCs treating fibrotic diseases.
Core Tip: Fibrosis is involved in various diseases. Adipose-derived stem cells (ASCs) are promising candidates for regenerative medicine and anti-fibrosis treatment. We herein discuss the mechanisms of action, changes in disease environment, ways to enhance therapeutic effects, as well as current preclinical and clinical studies of ASCs treating fibrotic diseases in order to provide a general picture.
